Summary
Oral application of 50 mg Etomoxir caused a significant rise (33.1 %) of insulin-mediated glucose uptake. This was shown in a placebo-controlled, double-blind randomized study in 8 type 2 diabetic patients by using the euglycemic clamp technique.
The mean metabolic clearance rate of glucose (MCR) was raised from 4.1±0.9 mg/(kg·min) to 5.4±1.2 mg/(kg·min) (x±SEM, P = 0.039). Plasma levels of free fatty acids (FFA), glucose counterregulatory hormones, lipids and C-peptide values during the clamps were not different after verum and placebo. We conclude that Etomoxir improves insulin sensitivity in type 2 diabetic patients.
Key words
CPTI-Inhibitor - Insulin Resistence - Type 2 Diabetes Mellitus - Etomoxir
